« Back to Search« Back to SearchSearch » A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS  Department of Health and Human Services, National Institutes of Health

A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS

  Bethesda, MD United States — Department of Health and Human Services, National Institutes of Health
Published July 12, 2016
|
Notice type
Prior notice
1. National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS 2017-1 will soon be available electronically through the NIH Small Business Research Funding Opportunities (http://sbir.nih.gov) Web site and at fedbizopps.gov. The SBIR Phase I, Fast-Track, Direct to Phase II Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site and fedbizopps.gov for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern AND (4) has, including its affiliates, no more than 500 employees*.* Note: For purposes of the SBIR program, this size standard is established by law. See 13 C.F.R. § 121.702. Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation PHS 2017-1:NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CANCER INSTITUTE (NCI): Cell and Animal-Based Models to Advance Cancer Health Disparity Research; Tools and Technologies for Monitoring RNA; Innovative Tools for Interrogating Tumor Microenvironment Dynamics; Modulating the Microbiome to Improve Therapeutic Efficacy of Cancer Therapeutics; Technologies for Differential Isolation of Exosomes and Oncosomes; Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies; Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer; Informatics Tools to Measure Cancer Care Coordination; Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving; Methods and Software for Integration of Cancer Metabolomic Data with Other -Omic and Imaging Data; Imaging Informatics Tools and Resources for Clinical Cancer Research; Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators; Predictive Biomarkers to Improve Radiation Treatment; Molecularly Targeted Radiation Therapy for Cancer Treatment; Development of Pediatric Cancer Drug Delivery Devices. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Development of a Drone to be used in Laboratory Automation Projects. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): Testing and Validation of Technologies for Inclusion in the CART Demonstration Project for Collaborative Aging Research; Inhalational 5A Apolipoprotein A-I Mimetic Peptide for the Treatment of Asthma (SBIR-TT); MRI Myocardial Needle Chemoablation Catheter; Membranous Ventricular Septal Defect (pmVSD) Transcatheter Occluder System; Transcatheter Occluder Device for Paravalvular Leaks. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA): Development of Novel Compounds to Treat Alcohol Use Disorder. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Effective Targeted Delivery of RNA-based Vaccines and Therapeutics; Simplified Sequencing for TB Drug Resistance Testing; Qualitative HIV RNA Home Test; Adjuvant Development; Vaccine Adjuvant Screening and Discovery; Database Resources Integration; Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections; Development of Microbiome-based Products for Infectious Diseases; Non-Invasive Rapid Diagnostics for Respiratory Diseases in Children; Phage-based Diagnostic Platforms for Rapid Detection of Bacterial Pathogens. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders; Analytical Tools and Approaches for (Multidimensional) Scholarly Research Assessment and Decision Support in the Biomedical Enterprise. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)NATIONAL CENTER FOR CHRONIC DISEASE AND HEALTH PROMOTION (NCCDPHP): Improve Contextual Awareness using Social Network Data. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): Multiplexed Digital Counting of Single Molecules for Advanced Molecular Diagnosis. 2. NIH/CDC SBIR Contract Solicitation PHS 2017-1, including proposal forms, will be available electronically on/around July 29, 2016 through the NIH Small Business Research Funding Opportunities Web site and at fedbizopps.gov. (Note: The PHS 2016-2 Omnibus Solicitation of the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Administration for Children and Families for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) GRANT Applications, where investigator-initiated ideas are encouraged, is open and is available at the same Web site noted above with a due dates of September 6, 2016, January 5, 2017, and April 5, 2017.) To understand better the differences between grants and contracts, see LINKURL:https://sbir.nih.gov/apply LINKURL: https://sbir.nih.gov/ LINKDESC: National Institutes of Health Small Business (SBIR/STTR) Research Funding Opportunities. E-mail: sbir@od.nih.govFor general information regarding the NIH/CDC SBIR program, please refer to:Office of Extramural Programs, Office of Extramural ResearchNational Institutes of HealthPhone: 301-435-2688E-mail: sbir@od.nih.gov Contracting Office Address: Office of Acquisitions5601 Fishers LaneSuite 300, MSC 9821Bethesda, Maryland 20892-9821

Full tender details available only for Oppex usersSign in

Fact Sheet

DATE
0712
YEAR
16
AGENCY
Department of Health and Human Services
OFFICE
National Institutes of Health
LOCATION
National Institute of Allergy and Infectious Diseases
ZIP
20892
CLASSCOD
A
NAICS
541712
OFFADD
Office of Acquisitions
SUBJECT
A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS
SOLNBR
PHS-2017-1
CONTACT
George W Kennedy, Contracting Officer, Phone 240-669-5170, Email kennedyg@mail.nih.gov - Tiffany Chadwick, Contracting Officer, Phone 240-276-7293, Email tiffany.chadwick@nih.gov
DESC
1. National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS 2017-1 will soon be available electronically through the NIH Small Business Research Funding Opportunities (http://sbir.nih.gov) Web site and at fedbizopps.gov. The SBIR Phase I, Fast-Track, Direct to Phase II Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site and fedbizopps.gov for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern AND (4) has, including its affiliates, no more than 500 employees*.* Note: For purposes of the SBIR program, this size standard is established by law. See 13 C.F.R. § 121.702. Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation PHS 2017-1:NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CANCER INSTITUTE (NCI): Cell and Animal-Based Models to Advance Cancer Health Disparity Research; Tools and Technologies for Monitoring RNA; Innovative Tools for Interrogating Tumor Microenvironment Dynamics; Modulating the Microbiome to Improve Therapeutic Efficacy of Cancer Therapeutics; Technologies for Differential Isolation of Exosomes and Oncosomes; Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies; Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer; Informatics Tools to Measure Cancer Care Coordination; Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving; Methods and Software for Integration of Cancer Metabolomic Data with Other -Omic and Imaging Data; Imaging Informatics Tools and Resources for Clinical Cancer Research; Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators; Predictive Biomarkers to Improve Radiation Treatment; Molecularly Targeted Radiation Therapy for Cancer Treatment; Development of Pediatric Cancer Drug Delivery Devices. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Development of a Drone to be used in Laboratory Automation Projects. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): Testing and Validation of Technologies for Inclusion in the CART Demonstration Project for Collaborative Aging Research; Inhalational 5A Apolipoprotein A-I Mimetic Peptide for the Treatment of Asthma (SBIR-TT); MRI Myocardial Needle Chemoablation Catheter; Membranous Ventricular Septal Defect (pmVSD) Transcatheter Occluder System; Transcatheter Occluder Device for Paravalvular Leaks. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA): Development of Novel Compounds to Treat Alcohol Use Disorder. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Effective Targeted Delivery of RNA-based Vaccines and Therapeutics; Simplified Sequencing for TB Drug Resistance Testing; Qualitative HIV RNA Home Test; Adjuvant Development; Vaccine Adjuvant Screening and Discovery; Database Resources Integration; Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections; Development of Microbiome-based Products for Infectious Diseases; Non-Invasive Rapid Diagnostics for Respiratory Diseases in Children; Phage-based Diagnostic Platforms for Rapid Detection of Bacterial Pathogens. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders; Analytical Tools and Approaches for (Multidimensional) Scholarly Research Assessment and Decision Support in the Biomedical Enterprise. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)NATIONAL CENTER FOR CHRONIC DISEASE AND HEALTH PROMOTION (NCCDPHP): Improve Contextual Awareness using Social Network Data. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): Multiplexed Digital Counting of Single Molecules for Advanced Molecular Diagnosis.
URL
https://www.fbo.gov/spg/HHS/NIH/NIAID/PHS-2017-1/listing.html
SETASIDE
Total Small Business

Oppex helps organizations with a professional approach to public sector sales, to either grow their business locally or find new opportunities abroad. We are the largest source of public procurement data in Europe. We process and translate public tenders from over 1.000 local, national and international procurement portals and have acquired over 8 million tenders in our database.


Trusted By

KONE
NHS
3M
ABB